NO20011085L - Tablett med umiddelbar frigivningsvirkning - Google Patents

Tablett med umiddelbar frigivningsvirkning

Info

Publication number
NO20011085L
NO20011085L NO20011085A NO20011085A NO20011085L NO 20011085 L NO20011085 L NO 20011085L NO 20011085 A NO20011085 A NO 20011085A NO 20011085 A NO20011085 A NO 20011085A NO 20011085 L NO20011085 L NO 20011085L
Authority
NO
Norway
Prior art keywords
immediate
tablet
release effect
release
effect
Prior art date
Application number
NO20011085A
Other languages
English (en)
Other versions
NO20011085D0 (no
Inventor
Sigbrit Forsman
Christer Karlsson
Magnus Karlsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20011085D0 publication Critical patent/NO20011085D0/no
Publication of NO20011085L publication Critical patent/NO20011085L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
NO20011085A 1998-09-03 2001-03-02 Tablett med umiddelbar frigivningsvirkning NO20011085L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9802973A SE9802973D0 (sv) 1998-09-03 1998-09-03 Immediate release tablet
PCT/SE1999/001471 WO2000013671A1 (en) 1998-09-03 1999-08-27 Immediate release tablet

Publications (2)

Publication Number Publication Date
NO20011085D0 NO20011085D0 (no) 2001-03-02
NO20011085L true NO20011085L (no) 2001-05-03

Family

ID=20412467

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20011085A NO20011085L (no) 1998-09-03 2001-03-02 Tablett med umiddelbar frigivningsvirkning

Country Status (32)

Country Link
US (3) US6521253B1 (no)
EP (2) EP1527787A1 (no)
JP (2) JP4026678B2 (no)
KR (2) KR20060097071A (no)
CN (3) CN1544088A (no)
AR (1) AR029313A1 (no)
AT (1) ATE286385T1 (no)
AU (1) AU746129B2 (no)
BR (1) BR9913400A (no)
CA (1) CA2341397C (no)
CZ (1) CZ300830B6 (no)
DE (1) DE69923074T2 (no)
EE (1) EE200100134A (no)
ES (1) ES2234296T3 (no)
HU (1) HU227278B1 (no)
ID (1) ID29629A (no)
IL (2) IL141439A0 (no)
IS (1) IS5869A (no)
MY (1) MY124359A (no)
NO (1) NO20011085L (no)
NZ (2) NZ539749A (no)
PL (1) PL195603B1 (no)
PT (1) PT1109537E (no)
RU (2) RU2252751C2 (no)
SA (1) SA99200683B1 (no)
SE (1) SE9802973D0 (no)
SK (1) SK285507B6 (no)
TR (2) TR200502188T2 (no)
TW (1) TW561056B (no)
UA (1) UA75567C2 (no)
WO (1) WO2000013671A1 (no)
ZA (1) ZA200101762B (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
BR0111868A (pt) * 2000-06-22 2003-07-01 Novartis Ag Composições farmacêuticas
US6462021B1 (en) 2000-11-06 2002-10-08 Astrazeneca Ab Use of low molecular weight thrombin inhibitor
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0103369D0 (sv) * 2001-10-09 2001-10-09 Astrazeneca Ab Pharmaceutical formulation
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
AU2003220909B2 (en) * 2002-03-28 2008-09-18 Teijin Limited Solid preparation containing single crystal form
SE0201658D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
DK1569912T3 (en) 2002-12-03 2015-06-29 Pharmacyclics Inc 2- (2-hydroxybiphenyl-3-yl) -1h-benzoimidazole-5-carboxamidine derivatives as factor VIIa inhibitors.
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
KR100574554B1 (ko) * 2004-05-28 2006-04-27 한미약품 주식회사 니아신의 경구투여용 서방성 조성물
US8022053B2 (en) * 2004-11-02 2011-09-20 Bayer Schering Pharma Aktiengesellschaft Oral solid dosage forms containing a low dose of estradiol
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
US8980337B2 (en) * 2006-06-29 2015-03-17 Tsumura & Co. Tablet composition containing kampo extract
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
CN101641339B (zh) 2007-02-01 2013-07-17 雷斯韦洛吉克斯公司 用于预防和治疗心血管疾病的化合物
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
DE102008014237A1 (de) * 2008-03-14 2009-09-17 J. Rettenmaier & Söhne Gmbh + Co. Kg Direktverpressbares Tablettierhilfsmittel
EP2407166B1 (en) * 2009-03-13 2013-08-21 Toyama Chemical Co., Ltd. Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
MX2021012876A (es) 2009-03-18 2022-06-23 Resverlogix Corp Nuevos agentes anti-inflamatorios.
ES2821018T3 (es) 2009-04-22 2021-04-23 Resverlogix Corp Nuevos agentes antiinflamatorios
PT2773354T (pt) 2011-11-01 2019-07-17 Resverlogix Corp Formulações orais de libertação imediata para quinazolinonas substituídas
US10213421B2 (en) 2012-04-04 2019-02-26 Alkahest, Inc. Pharmaceutical formulations comprising CCR3 antagonists
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
AU2013365926B9 (en) 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
GB201400034D0 (en) * 2014-01-02 2014-02-19 Astrazeneca Ab Pharmaceutical Compositions comprising AZD9291
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1601833A (en) 1978-02-06 1981-11-04 Wellcome Found Antacid formulation
US4517179A (en) * 1983-04-29 1985-05-14 Pennwalt Corporation Rapid dissolving, uniform drug compositions and their preparation
IT1200178B (it) 1986-07-23 1989-01-05 Alfa Farmaceutici Spa Formulazioni galeniche a cessione programmata contenenti farmaci ad attivita' antiflogistica
AR240018A1 (es) * 1987-10-07 1990-01-31 Merrell Pharma Inc Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol.
US5430023A (en) 1990-09-28 1995-07-04 Eli Lilly And Company Tripeptide antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
US5532267A (en) 1992-02-10 1996-07-02 Torii & Co., Ltd. Amidinonaphthyl furancarboxylate derivatives and acid addition salts therof
US5470955A (en) 1993-02-02 1995-11-28 Dartmouth College Antibodies which specifically bind mcl-1 polypeptide
SE9301916D0 (sv) 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
US5436229A (en) * 1994-03-04 1995-07-25 Eli Lilly And Company Bisulfite adducts of arginine aldehydes
MX9700152A (es) 1994-07-08 1997-04-30 Astra Ab Nueva formulacion farmaceutica oral, que contiene sal de magnesio de omeprazol.
US5510369A (en) * 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
US5733578A (en) 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
TW430561B (en) 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
TW541316B (en) * 1995-12-21 2003-07-11 Astrazeneca Ab Prodrugs of thrombin inhibitors
EP0803251B1 (en) 1996-04-23 2002-07-17 Janssen Pharmaceutica N.V. Immediate release pH-independent solid dosage form of cisapride
SE9601556D0 (sv) * 1996-04-24 1996-04-24 Astra Ab New pharmaceutical formulation of a thrombin inhibitor for parenteral use
DE19628617A1 (de) * 1996-07-16 1998-01-22 Basf Ag Direkttablettierhilfsmittel
EP0946178A4 (en) * 1996-09-18 2003-05-07 Merck & Co Inc COMBINATION THERAPY TO REDUCE THE RISKS OF HEART CIRCULAR DISEASES
HRP970493A2 (en) 1996-09-23 1998-08-31 Wienman E. Phlips Oral delayed immediate release medical formulation and method for preparing the same
SE9603724D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New pharmaceutical parenteral formulation of a thrombin inhibitor
US5798377A (en) * 1996-10-21 1998-08-25 Merck & Co., Inc. Thrombin inhibitors
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
GB9814215D0 (en) 1998-07-01 1998-09-02 Norton Healthcare Ltd Anti-inflammatory pharmaceutical formulations
CA2239931A1 (en) 1998-07-15 2000-01-15 Bernard Charles Sherman Pharmaceutical tablet comprising norfloxacin
US6368625B1 (en) 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
US6602521B1 (en) 1998-09-29 2003-08-05 Impax Pharmaceuticals, Inc. Multiplex drug delivery system suitable for oral administration
CA2366791A1 (en) 1999-04-06 2000-10-12 Kamal K. Midha Pharmaceutical dosage form for pulsatile delivery of d-threo-methylphenidate and a second cns stimulant
FI4823U1 (fi) 1999-04-13 2001-02-16 Beecham Pharm Pte Ltd Muunnetulla tavalla vapauttava lääkeformulaatio

Also Published As

Publication number Publication date
SK285507B6 (sk) 2007-03-01
WO2000013671A1 (en) 2000-03-16
CN1951371A (zh) 2007-04-25
KR100696350B1 (ko) 2007-03-20
RU2005100986A (ru) 2006-06-20
NO20011085D0 (no) 2001-03-02
PT1109537E (pt) 2005-04-29
HU227278B1 (en) 2011-01-28
IS5869A (is) 2001-02-28
IL141439A0 (en) 2002-03-10
ID29629A (id) 2001-09-06
IL141439A (en) 2006-07-05
CA2341397A1 (en) 2000-03-16
CN1315855A (zh) 2001-10-03
NZ539749A (en) 2006-11-30
NZ509943A (en) 2004-01-30
HUP0103886A3 (en) 2002-08-28
AU746129B2 (en) 2002-04-18
EP1109537A1 (en) 2001-06-27
AR029313A1 (es) 2003-06-25
PL195603B1 (pl) 2007-10-31
TW561056B (en) 2003-11-11
EP1109537B1 (en) 2005-01-05
ATE286385T1 (de) 2005-01-15
CN1158070C (zh) 2004-07-21
RU2252751C2 (ru) 2005-05-27
MY124359A (en) 2006-06-30
CZ2001774A3 (cs) 2001-10-17
US20030118644A1 (en) 2003-06-26
KR20060097071A (ko) 2006-09-13
SK2812001A3 (en) 2001-09-11
UA75567C2 (en) 2006-05-15
ES2234296T3 (es) 2005-06-16
SE9802973D0 (sv) 1998-09-03
DE69923074D1 (de) 2005-02-10
ZA200101762B (en) 2002-06-03
EE200100134A (et) 2002-06-17
JP4026678B2 (ja) 2007-12-26
BR9913400A (pt) 2001-05-22
US20050208128A1 (en) 2005-09-22
AU5892499A (en) 2000-03-27
CZ300830B6 (cs) 2009-08-19
HUP0103886A2 (hu) 2002-04-29
US6875446B2 (en) 2005-04-05
TR200502188T2 (tr) 2006-12-21
SA99200683B1 (ar) 2006-12-05
JP2002524412A (ja) 2002-08-06
JP2007039472A (ja) 2007-02-15
CA2341397C (en) 2009-02-03
EP1527787A1 (en) 2005-05-04
CN1544088A (zh) 2004-11-10
PL346545A1 (en) 2002-02-11
US6521253B1 (en) 2003-02-18
DE69923074T2 (de) 2005-12-08
TR200100666T2 (tr) 2001-08-21
KR20010090436A (ko) 2001-10-18

Similar Documents

Publication Publication Date Title
NO20011085D0 (no) Tablett med umiddelbar frigivningsvirkning
NO20004773D0 (no) Forlenget-frigjøringsblandinger
FI973816A0 (fi) Polypropen med hoeg smaeltstyrka
DE69937780D1 (de) Weiche Kautablette
ID27841A (id) Turunan-turunan biaril terapeutik
DE69930846D1 (de) Mehrkonfiguration-rückwand
IS5425A (is) Læknislyf
PT1060695E (pt) Cadeira empilhavel
LV12624B (lv) Tienilazolilalkosietanamini to iegusanas panemiens un pielietojums medikamentu legusana
DK0966287T3 (da) Oxacarbazepinfilmovertrukne tabletter
NO992692D0 (no) Nefadozon doseringsform
DE50000494D1 (de) Funktionsträgeranordnung
ID23735A (id) Tablet trovafloksasin mesilat
DE59813583D1 (de) Tablettentestgerät
ATE237529T1 (de) Tablettenspender
DK1074250T3 (da) Sukkerovertrukne tabletter
DK1176982T3 (da) Prucaloprid oral opløsning
DE29801440U1 (de) Tabletten-Einnahmehilfe
DE29621865U1 (de) Portions-Tablette
NO992607D0 (no) System med sÕrhelende virkning
DE29813269U1 (de) Tablette
FI19992468A (fi) Tuoli
DE29823505U1 (de) Punkttablette
UA2845S (uk) Таблетка
UA2855S (uk) Таблетка фармацевтична

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application